6 news items
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
SEEL
16 May 24
on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with CNS disorders and other rare
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
SEEL
14 May 24
biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients
"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment
CMPS
CYBN
DRUG
7 May 24
an expert committee will examine the evidence behind the application.Lykos Therapeutics (formerly MAPS Public Benefit Corporation) announced
Seelos Therapeutics Provides Update On Top-Line Results From Its Amyotrophic Lateral Sclerosis Study With SLS-005
SEEL
19 Mar 24
as an influential force in ALS research and in caring for the ALS community. Their unique and innovative approach continues to be a benefit
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
SEEL
19 Mar 24
. Their unique and innovative approach continues to be a benefit to the ALS community and its contributions have helped bring the last two FDA approved
j01biwo2dce7naefifvvk202mhrwvcdvmi4ky
ATAI
CMND
CMPS
14 Mar 24
proven medical benefits."
Charbonneau, the sponsor of the standalone psilocybin measure, said late last year that he was already
- Prev
- 1
- Next